LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
USA - NASDAQ:LGND - US53220K5048 - Common Stock
166.24 USD
+0.73 (+0.44%)
165.435 USD
-0.81 (-0.48%)
Taking everything into account, LGND scores 5 out of 10 in our fundamental rating. LGND was compared to 196 industry peers in the Pharmaceuticals industry. While LGND has a great health rating, its profitability is only average at the moment. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
In the past year LGND had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
In the past 5 years LGND always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -8.00%, LGND is in the better half of the industry, outperforming 69.39% of the companies in the same industry.
LGND's Return On Equity of -9.16% is fine compared to the rest of the industry. LGND outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGND's Operating Margin has declined in the last couple of years.
The Gross Margin of LGND (93.05%) is better than 95.92% of its industry peers.
LGND's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LGND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LGND has been increased compared to 1 year ago.
Compared to 5 years ago, LGND has more shares outstanding
LGND has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 17.40 indicates that LGND is not in any danger for bankruptcy at the moment.
The Altman-Z score of LGND (17.40) is better than 91.33% of its industry peers.
There is no outstanding debt for LGND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.4 |
ROIC/WACCN/A
WACC9.81%
2.3 Liquidity
LGND has a Current Ratio of 5.45. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND has a better Current ratio (5.45) than 72.45% of its industry peers.
LGND has a Quick Ratio of 5.21. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND's Quick ratio of 5.21 is fine compared to the rest of the industry. LGND outperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.80% over the past year.
The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 40.53%.
The Revenue has been growing slightly by 6.80% on average over the past years.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
3.2 Future
LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.82% yearly.
The Revenue is expected to grow by 20.10% on average over the next years. This is a very strong growth
EPS Next Y22.58%
EPS Next 2Y15.32%
EPS Next 3Y14.82%
EPS Next 5Y13.82%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.1%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 27.52 indicates a quite expensive valuation of LGND.
Based on the Price/Earnings ratio, LGND is valued cheaply inside the industry as 80.10% of the companies are valued more expensively.
LGND's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.20.
The Price/Forward Earnings ratio is 21.89, which indicates a rather expensive current valuation of LGND.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 75.00% of the companies listed in the same industry.
LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.52 | ||
| Fwd PE | 21.89 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 76.53% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 78.06% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.08 | ||
| EV/EBITDA | 139.46 |
4.3 Compensation for Growth
LGND's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 14.82% in the coming years.
PEG (NY)1.22
PEG (5Y)2.05
EPS Next 2Y15.32%
EPS Next 3Y14.82%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
166.24
+0.73 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.76%
Inst Owner Change1.65%
Ins Owners1.71%
Ins Owner Change1.29%
Market Cap3.26B
Analysts84.62
Price Target186.79 (12.36%)
Short Float %6.04%
Short Ratio4.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)25.43%
PT rev (3m)27.28%
EPS NQ rev (1m)3.7%
EPS NQ rev (3m)20.84%
EPS NY rev (1m)12.06%
EPS NY rev (3m)12.37%
Revenue NQ rev (1m)5.41%
Revenue NQ rev (3m)18.31%
Revenue NY rev (1m)10.66%
Revenue NY rev (3m)10.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.52 | ||
| Fwd PE | 21.89 | ||
| P/S | 17.37 | ||
| P/FCF | 64.08 | ||
| P/OCF | 61.96 | ||
| P/B | 3.93 | ||
| P/tB | 11.5 | ||
| EV/EBITDA | 139.46 |
EPS(TTM)6.04
EY3.63%
EPS(NY)7.59
Fwd EY4.57%
FCF(TTM)2.59
FCFY1.56%
OCF(TTM)2.68
OCFY1.61%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.22
PEG (5Y)2.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% | ||
| FCFM | 27.11% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.04% | ||
| Cap/Sales | 0.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 259.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 17.4 |
F-Score5
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y22.58%
EPS Next 2Y15.32%
EPS Next 3Y14.82%
EPS Next 5Y13.82%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.1%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year483.19%
EBIT Next 3Y133.64%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A